16 results on '"Elford HL"'
Search Results
2. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
- Author
-
Mayhew CN, Sumpter R, Inayat M, Cibull M, Phillips JD, Elford HL, and Gallicchio VS
- Subjects
- Animals, Antiviral Agents administration & dosage, B-Lymphocytes immunology, Benzamidines administration & dosage, Drug Therapy, Combination, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors therapeutic use, Female, Hydroxamic Acids administration & dosage, Hydroxyurea administration & dosage, Leukemia Virus, Murine drug effects, Leukemia, Experimental drug therapy, Leukemia, Experimental virology, Lymphocyte Activation drug effects, Mice, Mice, Inbred C57BL, Murine Acquired Immunodeficiency Syndrome virology, Retroviridae Infections drug therapy, Retroviridae Infections virology, Ribonucleotide Reductases antagonists & inhibitors, Treatment Outcome, Tumor Virus Infections drug therapy, Tumor Virus Infections virology, Antiviral Agents therapeutic use, Benzamidines therapeutic use, Didanosine therapeutic use, Hydroxamic Acids therapeutic use, Hydroxyurea therapeutic use, Murine Acquired Immunodeficiency Syndrome drug therapy, Reverse Transcriptase Inhibitors therapeutic use
- Abstract
The ribonucleotide reductase inhibitor hydroxyurea (HU) has demonstrated some benefit as a component of drug cocktails for the treatment of HIV-1 infection. However, HU is notoriously myelosuppressive and often administered only as salvage therapy to patients with late-stage disease, potentially exacerbating the bone marrow toxicity of HU. In this report we have compared the antiviral effects of HU and two novel RR inhibitors trimidox (3,4,5-trihydroxybenzamidoxime) and didox (3,4-dihydroxybenzohydroxamic acid) in combination with didanosine (2,3-didoxyinosine; ddI) in the LPBM5 MuLV retrovirus model (murine AIDS). We also evaluated the effects of these drug combinations on the hematopoietic tissues of LPBM5 MuLV-infected animals. The combination of RR inhibitors and ddI was extremely effective (DX>TX>HU) in inhibiting development of retrovirus-induced disease (splenomegaly, hypergammaglobulinemia, activated B-splenocytes and loss of splenic architecture). In addition, relative levels of proviral DNA were significantly lower in combination drug-treated animals compared to infected controls. Evaluation of femur cellularity, numbers of marrow-derived myeloid progenitor cells (CFU-GM and BFU-E) and peripheral blood indices revealed that TX and DX in combination with ddI were well-tolerated. However, treatment with HU and ddI induced moderate myelosuppression. These data demonstrate that RR inhibitors in combination with ddI provide significant protection against retroviral disease in murine AIDS. Moreover, the novel RR inhibitors TX and DX appear to be more effective and less myelosuppressive than HU when administered with ddI in this model.
- Published
- 2005
- Full Text
- View/download PDF
3. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.
- Author
-
Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, Greenberg RN, Elford HL, and Gallicchio VS
- Subjects
- Animals, Benzamidines chemistry, Benzamidines therapeutic use, DNA, Viral, Female, Femur cytology, Femur drug effects, Free Radical Scavengers chemistry, Free Radical Scavengers therapeutic use, Hematopoietic Stem Cells drug effects, Hydroxamic Acids chemistry, Hydroxamic Acids therapeutic use, Hydroxyurea chemistry, Hydroxyurea therapeutic use, Hypergammaglobulinemia drug therapy, Leukemia Virus, Murine genetics, Leukemia, Experimental blood, Leukemia, Experimental drug therapy, Leukemia, Experimental immunology, Mice, Mice, Inbred C57BL, Murine Acquired Immunodeficiency Syndrome blood, Murine Acquired Immunodeficiency Syndrome drug therapy, Murine Acquired Immunodeficiency Syndrome immunology, Proviruses genetics, Retroviridae Infections blood, Retroviridae Infections drug therapy, Retroviridae Infections immunology, Spleen pathology, Splenomegaly, Tumor Virus Infections blood, Tumor Virus Infections drug therapy, Tumor Virus Infections immunology, Benzamidines adverse effects, Bone Marrow Cells drug effects, Free Radical Scavengers adverse effects, Hydroxamic Acids adverse effects, Hydroxyurea adverse effects, Leukemia Virus, Murine drug effects, Leukemia, Experimental pathology, Murine Acquired Immunodeficiency Syndrome pathology, Retroviridae Infections pathology, Ribonucleotide Reductases antagonists & inhibitors, Tumor Virus Infections pathology
- Abstract
Recently, the use of the ribonucleotide reductase (RR) inhibitor hydroxyurea (HU) in combination with nucleoside analogs has gained attention as a potential strategy for anti-HIV-1 therapy. However, appeal for the long-term use of HU in HIV-1 infection may be limited by its propensity to induce hematopoietic toxicity. We report a comparison of the efficacy and bone marrow toxicity of HU (400 and 200 mg/kg/day) with the novel RR inhibitors and free radical-scavenging compounds didox (DX; 3,4-dihydroxybenzohydroxamic acid; 350 mg/kg/day) and trimidox (TX; 3,4,5-trihydroxybenzamidoxime; 175 mg/kg/day) in the murine AIDS (LPBM5 MuLV) model of retrovirus infection. Infected mice received daily drug treatment for 8 weeks. Efficacy was determined by measuring drug effects on retroviral-induced disease progression (i.e. development of splenomegaly and hypergammaglobulinemia) and by evaluating splenic levels of proviral DNA. Bone marrow toxicity was evaluated by measuring peripheral blood indices (WBC, hematocrit and reticulocyte counts), femoral cellularity and by determining the numbers of hematopoietic progenitor cells (CFU-GM, BFU-E) per femur and spleen. Compared to infected controls receiving no drug treatment, disease progression was significantly suppressed by TX, DX and HU. However, HU was associated with mortality and induced significant hematopoietic toxicity in a time- and dose-dependent manner. Conversely, TX and DX effectively inhibited retrovirus-induced disease but did not induce hematopoietic toxicity. These results suggest that due to their reduced hematopoietic toxicity and ability to inhibit disease progression in murine AIDS, TX and DX may offer effective alternatives to HU therapy in HIV-1 infection., (Copyright 2002 Elsevier Science B.V.)
- Published
- 2002
- Full Text
- View/download PDF
4. Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.
- Author
-
Mayhew CN, Phillips JD, Cibull ML, Elford HL, and Gallicchio VS
- Subjects
- Animals, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Benzamidines administration & dosage, Benzamidines adverse effects, Blood Cell Count, Body Weight drug effects, Bone Marrow pathology, Hydroxamic Acids administration & dosage, Hydroxamic Acids adverse effects, Hydroxyurea therapeutic use, Lymphoproliferative Disorders pathology, Lymphoproliferative Disorders virology, Mice, Spleen drug effects, Spleen pathology, Time Factors, Antiviral Agents adverse effects, Benzamidines therapeutic use, Bone Marrow drug effects, Hydroxamic Acids therapeutic use, Hydroxyurea adverse effects, Leukemia Virus, Murine physiology, Lymphoproliferative Disorders drug therapy
- Abstract
We evaluated the ability of a short course of treatment with the ribonucleotide reductase (RR) inhibitor hydroxyurea (HU) and two novel RR inhibitors Trimidox (TX) and Didox (DX) to influence late-stage murine retrovirus-induced lymphoproliferative disease. LPBM5 murine leukaemia virus retrovirus-infected mice were treated daily with HU, TX or DX for 4 weeks, beginning 9 weeks post-infection, after development of immunodeficiency and lymphoproliferative disease. Drug effects on disease progression were determined by evaluating spleen weight and histology. Effects on haematopoiesis were determined by measuring peripheral blood indices (white blood cells and haematocrit) and assay of femur cellularity and femoral and splenic content of colony-forming units granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). HU, TX and DX partially reversed late-stage retrovirus-induced disease, resulting in spleen weights significantly below pre-treatment values. Spleen histology was also improved by RR inhibitor treatment (DX>TX>HU). However, as expected, HU was significantly myelosuppressive, inducing a reduction in peripheral indices associated with depletion of femoral CFU-GM and BFU-E. In contrast, although TX and DX were moderately myelosuppressive, both drugs were significantly better tolerated than HU. In summary, short-term treatment in late-stage murine retroviral disease with HU, TX or DX induced dramatic reversal of disease pathophysiology. However, the novel RR inhibitors TX and DX had more effective activity and significantly less bone marrow toxicity than HU.
- Published
- 2002
- Full Text
- View/download PDF
5. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
- Author
-
Fritzer-Szekeres M, Salamon A, Grusch M, Horvath Z, Höchtl T, Steinbrugger R, Jäger W, Krupitza G, Elford HL, and Szekeres T
- Subjects
- Apoptosis, Arabinofuranosylcytosine Triphosphate metabolism, Cell Division drug effects, Cytarabine metabolism, DNA drug effects, DNA metabolism, Drug Screening Assays, Antitumor, Drug Synergism, HL-60 Cells, Humans, Leukemia, Promyelocytic, Acute, Nucleic Acid Synthesis Inhibitors metabolism, Benzamidines pharmacology, Cytarabine pharmacology, Enzyme Inhibitors pharmacology, Nucleic Acid Synthesis Inhibitors pharmacology, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Ribonucleotide reductase is the rate-limiting enzyme for the de novo synthesis of deoxynucleoside triphosphates and therefore represents a good target for cancer chemotherapy. Trimidox (3,4,5-trihydroxybenzamidoxime) was identified as a potent inhibitor of this enzyme and was shown to significantly decrease deoxycytidine triphosphate (dCTP) pools in HL-60 leukemia cells. We now investigated the ability of trimidox to increase the antitumor effect of 1-beta-D-arabinofuranosyl cytosine (Ara-C). Ara-C is phosphorylated by deoxycytidine kinase, which is subject to negative allosteric regulation by dCTP. Therefore, a decrease of dCTP may cause increased Ara-C phosphorylation and enhanced incorporation of Ara-C into DNA. Ara-C incorporation indeed increased 1.51- and 1.89-fold after preincubation with 75 and 100 microM trimidox, respectively. This was due to the significantly increased 1-beta-D-arabinofuranosyl cytosine triphosphate pools (1.9- and 2.5-fold) after preincubation with trimidox. We also investigated the effects of a combination of trimidox and Ara-C on the colony formation of HL-60 cells. A synergistic potentiation of the effect of Ara-C could be observed, when trimidox was added. Trimidox, which decreases intracellular deoxynucleoside triphosphate concentrations thus leading to apoptosis, enhanced the induction of apoptosis caused by Ara-C. We conclude, that trimidox is capable of synergistically enhancing the effects of Ara-C and therefore this drug combination might be further tested in animals.
- Published
- 2002
- Full Text
- View/download PDF
6. The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells.
- Author
-
Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters GJ, Szekeres T, and Krupitza G
- Subjects
- Cyclin D1 biosynthesis, Deoxyribonucleotides metabolism, Drug Screening Assays, Antitumor, Female, Gene Expression drug effects, Genes, cdc drug effects, HL-60 Cells, Humans, Ribonucleotide Reductases antagonists & inhibitors, Tumor Cells, Cultured, Urokinase-Type Plasminogen Activator biosynthesis, cdc25 Phosphatases biosynthesis, Antineoplastic Agents pharmacology, Apoptosis genetics, Benzamidines pharmacology, Enzyme Inhibitors pharmacology, Genes, myc, Ovarian Neoplasms drug therapy
- Abstract
Trimidox (3,4,5-trihydroxybenzohydroxamidoxime), a recently synthesized inhibitor of ribonucleotide reductase (RR), was shown to exert anti-proliferative activities in HL-60 and K562 human leukemia cell lines and to prolong the life span of mice inoculated with L1210 mouse leukemia cells. Here we test whether trimidox also exhibits anti-neoplastic properties in ovarian carcinoma cells. Since the mode of action of trimidox on cell fate has not been investigated so far, we addressed this unresolved item and find that this polyhydroxybenzoic acid derivative induces apoptosis of N.1 human ovarian carcinoma cells when tested in growth factor deprived medium. Utilizing an improved analysis, based on Hoechst 33258/propidium iodide double staining, apoptosis is quantified and discriminated from necrosis. Trimidox induces c-myc expression, which is indispensible for apoptosis of N.1 cells, and expression of plasminogen activator/urokinase type (upa), which supports the apoptotic process under more physiological conditions. Surprisingly, trimidox does not block dNTP synthesis in N.1 cells at the concentrations tested and, therefore, trimidox induces apoptosis independent of RR-inhibition. Like TNFalpha or benzamide riboside, which are also inducers of apoptosis of N.1 cells, trimidox also down-regulates the G1 cell cycle phosphatase cdc25A, whereas cyclin D1 becomes up-regulated. This report shows that trimidox destroys human ovarian carcinoma cells by inducing them to undergo apoptosis as well as corroborating previous investigations which demonstrated that apoptosis of these cells depends on c-myc over-expression when survival factors are withdrawn.
- Published
- 2000
- Full Text
- View/download PDF
7. Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells.
- Author
-
Fritzer-Szekeres M, Grusch M, Luxbacher C, Horvath S, Krupitza G, Elford HL, and Szekeres T
- Subjects
- Antineoplastic Agents pharmacology, Bisbenzimidazole, DNA Fragmentation, Enzyme Activation drug effects, Fas Ligand Protein, Fluorescent Dyes, Gelsolin metabolism, Gene Expression drug effects, Genes, myc, HL-60 Cells, Humans, Membrane Glycoproteins analysis, Poly(ADP-ribose) Polymerases metabolism, Propidium, fas Receptor analysis, Apoptosis drug effects, Benzamidines pharmacology, Caspases metabolism, Enzyme Inhibitors pharmacology, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Ribonucleotide reductase (RR) is the rate-limiting enzyme for the de novo synthesis of deoxyribonucleotides. Its activity is significantly increased in tumor cells related to the proliferation rate. Therefore, the enzyme is considered to be an excellent target for cancer chemotherapy. In the present study, we investigated whether the antineoplastic effects of trimidox (3,4, 5-trihydroxybenzamidoxime), a novel inhibitor of RR, were due to induction of apoptosis.HL-60 cells were incubated with various concentrations of trimidox. Consequently, cell morphology, DNA condensation, annexin binding, DNA fragmentation, and signature type cleavage of poly(ADP-ribose)polymerase and gelsolin were determined. We also tested the involvement of CD95 and CD95 ligand in apoptosis induction. Furthermore, we examined the c-myc expression of HL-60 cells after incubation with trimidox in order to elucidate a possible association between c-myc expression and induction of apoptosis in the case of trimidox. Trimidox incubation caused a time-dependent increase of c-myc RNA expression and this was accompanied by the induction of apoptosis. Apoptosis was triggered independently of CD95 by the activation of caspases and PARP cleavage. We conclude that trimidox is able to induce programmed cell death. The induction of apoptosis was demonstrated by various biochemical and morphological methods and seems to be associated with the induction of c-myc. Apoptosis was induced by the activation of caspases and without change of the CD95 and CD95 ligand expression.
- Published
- 2000
- Full Text
- View/download PDF
8. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
- Author
-
Iyamu WE, Adunyah SE, Fasold H, Horiuchi K, Elford HL, Asakura T, and Turner EA
- Subjects
- Antineoplastic Agents therapeutic use, Benzamidines therapeutic use, Cell Differentiation drug effects, Cell Division drug effects, Drug Therapy, Combination, Humans, Hydroxamic Acids therapeutic use, K562 Cells metabolism, Ribonucleotide Reductases antagonists & inhibitors, Benzamidines pharmacology, Enzyme Inhibitors pharmacology, Fetal Hemoglobin biosynthesis, Hemoglobin, Sickle biosynthesis, Hydroxamic Acids pharmacology, K562 Cells cytology, Streptozocin therapeutic use
- Abstract
Upon appropriate drug treatment, the human erythroleukemic K562 cells have been shown to produce hemoglobin and F-cells. Fetal hemoglobin (Hb F) inhibits the polymerization events of sickle hemoglobin (Hb S), thereby ameliorating the clinical symptoms of sickle cell disease. Ribonucleotide reductase inhibitors (RRIs) have been shown to inhibit the growth of myeloid leukemia cells leading to the production of Hb F upon differentiation. Of the RRIs currently in use, hydroxyurea is the most effective agent for Hb F induction. We have examined the capacity of two novel RRIs, didox (DI) and trimidox (TRI), in combination with streptozotocin (STZ), to induce hemoglobin and F-cell production. The K562 cells were cultured with different concentrations of didox-STZ or trimidox-STZ at a fixed molar ratio of 3:1 and 1:5 for 96 hr, respectively. At pre-determined time intervals, aliquots of cells were obtained and total hemoglobin (benzidine positive) levels, number of F-cells, and Hb F were determined by the differential staining technique, fetal hemoglobin assay kit, and fluorescence cytometry respectively. The effect of combined drug treatment on the growth of K562 cells was examined by isobologram analysis. Our results indicate that a synergistic growth-inhibitory differentiation effect occurred when didox or trimidox was used in combination with STZ on K562 cells. There was an increase in the number of both benzidine-positive normoblasts and F-cells, accompanied by morphologic appearances typical of erythroid maturation. On day 4, the number of benzidine-positive cells showed a 6-9-fold increase and the number of F-cells was between 2.5- and 5.7-fold higher than the respective controls. Based upon these results, treatment with a ribonucleotide reductase inhibitor, such as didox or trimidox, in combination with STZ, might offer an additional promising option in sickle cell disease therapy., (Copyright 2000 Wiley-Liss, Inc.)
- Published
- 2000
- Full Text
- View/download PDF
9. Apoptosis-inducing cleavage of caspases by trimidox, an inhibitor of ribonucleotide reductase.
- Author
-
Fritzer-Szekeres M, Luxbacher C, Horvath Z, Grusch M, Krupitza G, Elford HL, and Szekeres T
- Subjects
- Caspase 3, DNA Fragmentation, Gene Expression drug effects, HL-60 Cells, Humans, Poly(ADP-ribose) Polymerases metabolism, Proto-Oncogene Proteins c-myc genetics, Apoptosis, Benzamidines pharmacology, Caspase Inhibitors, Enzyme Inhibitors pharmacology, Ribonucleotide Reductases antagonists & inhibitors
- Published
- 2000
- Full Text
- View/download PDF
10. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
- Author
-
Mayhew CN, Phillips JD, Greenberg RN, Birch NJ, Elford HL, and Gallicchio VS
- Subjects
- Acquired Immunodeficiency Syndrome drug therapy, Anemia chemically induced, Animals, Cells, Cultured, Colony-Forming Units Assay, Female, Femur, Hematopoiesis drug effects, Humans, In Vitro Techniques, Lymphocytes cytology, Lymphocytes drug effects, Macrophages cytology, Macrophages drug effects, Mice, Mice, Inbred C57BL, Neutrophils cytology, Neutrophils drug effects, Organ Size, Spleen cytology, Anti-HIV Agents toxicity, Benzamidines toxicity, Enzyme Inhibitors toxicity, Hematopoietic Stem Cells drug effects, Hydroxamic Acids toxicity, Hydroxyurea toxicity, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Inhibitors of the cellular enzyme ribonucleotide reductase (hydroxyurea, [HU]) have been proposed as a new therapeutic strategy for the treatment of HIV type-1 (HIV-1) infection. However, HU use may be limited by the frequent development of hematopoietic toxicity. We report here short-term hematopoietic toxicity in mice receiving HU when compared to either of two more potent enzyme inhibitors, didox (DX) and trimidox (TX). High dose HU, DX, and TX monotherapy (500, 460, and 220 mg/kg/day respectively) was administered by daily i.p. injection (Monday-Friday) to C57BL/6 mice for 10 weeks. Effects on hematopoiesis were established by quantitating peripheral blood indices (hematocrit, hemoglobin, mean corpuscular volume, mean cell hemoglobin, mean corpuscular hemoglobin concentration, RBC, and WBC) and numbers of colony-forming units-granulocyte-macrophage (CFU-GM) and BFU-E from bone marrow and spleen. HU produced rapid induction of a macrocytic hypochromic anemia and altered white blood cell kinetics associated with myelosuppression defined as reduced marrow organ cellularity and induction of splenic extramedullary hematopoiesis. Compared to HU, TX and DX induced fewer changes in peripheral blood indices and CFU-GM and BFU-E per hematopoietic organ. In vitro human and murine marrow CFU-GM and BFU-E colony formations were assayed in the presence of dose escalation HU, DX, or TX (0, 1, 10, 50, 100, and 200 microM). HU inhibited colony formation more than either DX or TX. These in vivo and in vitro studies suggest that novel ribonucleotide reductase inhibitors TX and DX may provide an effective alternative to HU in HIV-1 therapy because they demonstrate reduced hematopoietic toxicity.
- Published
- 1999
- Full Text
- View/download PDF
11. Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells.
- Author
-
Iyamu EW, Adunyah SE, Elford HL, Fasold H, and Turner EA
- Subjects
- Cell Division drug effects, Enzyme Inhibitors, Erythroid Precursor Cells cytology, Erythroid Precursor Cells drug effects, Fetal Hemoglobin metabolism, Histocytochemistry, Humans, Leukemia, Erythroblastic, Acute metabolism, Tumor Cells, Cultured, Benzamidines pharmacology, Cell Differentiation drug effects, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Trimidox (3,4,5-trihdroxybenzamidoxime) has been shown to reduce the activity of ribonucleotide reductase with accompanied growth inhibition and differentiation of mammalian cells. Hydroxyurea (HU) is the only ribonucleotide reductase inhibitor in clinical use for the treatment and management of sickle cell anemia, since this compound increases fetal hemoglobin (Hb F) production: a potent inhibitor of sickle hemoglobin (Hb SS) polymerization. However, the main limitations of HU is its lack of potency, myelosuppression and short half life. These studies investigated the effects of trimidox on the induction of hemoglobin and F-cells production in K562 erythroleukemia cells. Our study reveals that trimidox exhibits concentration dependent inhibitory effect on K562 cells with increase in benzidine positive normoblasts and F-cells production as well as morphological changes typical of erythroid differentiation. These findings provide the first evidence that the growth inhibitory differentiation of cells induced by trimidox enhance hemoglobin and F-cells production.
- Published
- 1998
- Full Text
- View/download PDF
12. Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
- Author
-
Fritzer-Szekeres M, Novotny L, Romanova D, Göbl R, Sedlak J, Vachalkova A, Rauko P, Elford HL, and Szekeres T
- Subjects
- Animals, Mice, Mice, Inbred DBA, Neoplasm Transplantation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzamidines therapeutic use, Doxorubicin therapeutic use, Enzyme Inhibitors therapeutic use, Leukemia L1210 drug therapy, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Ribonucleotide reductase is the rate limiting enzyme of de novo DNA synthesis; its activity is significantly increased in tumor cells related to the proliferation rate. Therefore the enzyme is considered to be an excellent target for cancer chemotherapy. In the present study we tested the in vitro and in vivo antitumor effects of a drug combination using trimidox (3,4,5-trihydroxybenzamidoxime), a novel inhibitor of ribonucleotide reductase with adriamycin, a widely used anticancer drug. This combination was selected because adriamycin generates free radicals being responsible for cardiotoxic side effects; trimidox has been shown to be a good free radical scavenger. The in vitro cytotoxic effect of the drug combination was examined in L1210 mouse leukemia cells employing a MTT chemosensitivity assay. Incubation of these cells with adriamycin and trimidox together yielded less than additive cytotoxic effects compared to either drug alone. These effects were not caused by the involvement of p-glycoprotein mediated drug efflux. However, when the effect of trimidox and adriamycin in combination was examined in L1210 leukemia bearing mice antitumor effects of adriamycin could be enhanced by the presence of trimidox. Our data indicate, that the in vivo combination of adriamycin together with trimidox might be beneficial for the treatment of malignancies.
- Published
- 1998
- Full Text
- View/download PDF
13. The new inhibitors of ribonucleotide reductase--comparison of some physico-chemical properties.
- Author
-
Romanova D, Vachalkova A, Szekeres T, Elford HL, and Novotny L
- Subjects
- Benzamidines pharmacology, Chromatography, High Pressure Liquid, Enzyme Inhibitors pharmacology, Hydrogen-Ion Concentration, Hydroxamic Acids pharmacology, Oximes pharmacology, Polarography, Spectrophotometry, Ultraviolet, Benzamidines chemistry, Enzyme Inhibitors chemistry, Hydroxamic Acids chemistry, Oximes chemistry, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Amidox (AX), didox (DX) and trimidox (TX), compounds synthetized as new ribonucleotide reductase inhibitors, have been investigated by ultraviolet (UV) spectrophotometry, polarography and high performance liquid chromatography (HPLC). The experiments have been performed at various pH values. The changes in UV absorption of the compounds studied were recorded and it was demonstrated that these changes are related to the pH and to structural features of the investigated molecules. From the compounds included in our series of experiments, only amidox and trimidox are reduced during polarographic experiments in Britton-Robinson buffer. The reduction of both compounds proceeded in two one-electron steps in acidic pH. One two-electron diffuse irreversible wave was observed at basic pH. The values of the half-wave potential became more negative in accordance with the increasing pH. HPLC assay also showed changes in the retention of compounds investigated, particularly when the pH of the mobile phase was close to the dissociation constant of the particular drug. The changes of physico-chemical properties detected by the all used methods are related to different chemical structures (the most significant changes were observed in alkaline pH).
- Published
- 1997
- Full Text
- View/download PDF
14. Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.
- Author
-
Szekeres T, Vielnascher E, Novotny L, Vachalkova A, Fritzer M, Findenig G, Göbl R, Elford HL, and Goldenberg H
- Subjects
- Cell Division drug effects, Cell Survival drug effects, Dose-Response Relationship, Drug, HL-60 Cells, Humans, Kinetics, Oxidation-Reduction, Polarography, Benzamidines chemistry, Benzamidines toxicity, Enzyme Inhibitors chemistry, Enzyme Inhibitors toxicity, Iron pharmacology, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Ribonucleotide reductase is the rate limiting enzyme of deoxynucleoside triphosphate synthesis and is considered to be an excellent target of cancer chemotherapy. Trimidox, a newly synthesized compound, inhibits this enzyme and has in vitro and in vivo antitumour activity. As trimidox was able to upregulate the expression of the transferrin receptor in HL-60 human promyelocytic leukaemia cells, we have now investigated the capability of trimidox to interfere with iron metabolism. We show by photometric and polarographic methods that trimidox is able for form an iron complex. However, its cytotoxic action cannot be circumvented by addition of iron-saturated transferrin or iron-ammonium citrate, indicating that the iron complexing capacity is not responsible for the mechanism of action of this compound. When HL-60, K562 or L1210 leukaemia cells were incubated with the trimidox-iron complex itself, we could observe increases of the 50% growth inhibitory capacity of the complex in comparison with trimidox alone. We conclude that trimidox is able to form an iron complex, but in contrast to other agents, the anticancer activity cannot be contributed to this effect alone. Further studies will have to elucidate the molecular mechanism of action of this new and promising anticancer agent.
- Published
- 1995
- Full Text
- View/download PDF
15. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells.
- Author
-
Szekeres T, Fritzer M, Strobl H, Gharehbaghi K, Findenig G, Elford HL, Lhotka C, Schoen HJ, and Jayaram HN
- Subjects
- Cell Differentiation drug effects, Cell Division drug effects, DNA Replication drug effects, DNA, Neoplasm biosynthesis, Deoxyribonucleotides analysis, Drug Synergism, Humans, Ribavirin pharmacology, Ribonucleotides analysis, Tumor Cells, Cultured drug effects, Benzamidines pharmacology, IMP Dehydrogenase antagonists & inhibitors, Leukemia, Promyelocytic, Acute pathology, Neoplasm Proteins antagonists & inhibitors, Ribavirin analogs & derivatives, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Increased ribonucleotide reductase (RR) activity has been linked with malignant transformation and tumor cell growth. Therefore, this enzyme is considered to be an excellent target for cancer chemotherapy. We have examined the effects of a newly patented RR inhibitor, trimidox (3,4,5-trihydroxybenzohydroxamidoxime). Trimidox inhibited the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 mumol/L. Incubation of HL-60 cells with 50 mumol/L trimidox for 24 hours decreased deoxyguanosine triphosphate (dGTP) and deoxycytidine triphosphate (dCTP) pools to 24% and 39% of control values, respectively. Incubation of HL-60 cells with 20 to 80 mumol/L trimidox even up to a period of 4 days did not alter the distribution of cells in different phases of cell cycle. Sequential incubation of HL-60 cells with trimidox (25 mumol/L) for 24 hours and then with 10 mumol/L tiazofurin (an inhibitor of inosine monophosphate dehydrogenase) for 4 days produced synergistic growth inhibitory activity, and the cell number decreased to 16% of untreated controls. When differentiation-linked cell surface marker expressions were determined in cells treated with trimidox and tiazofurin, a significantly increased fluorescence intensity was observed for the CD 11b (2.9-fold). CD 33 (1.9-fold), and HLA-D cell surface antigens. Expression of the transferrin receptor (CD71) increased 7.3-fold in cells treated with both agents, compared with untreated controls. Our results suggest that trimidox in combination with tiazofurin might be useful in the treatment of leukemia.
- Published
- 1994
16. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
- Author
-
Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van't Riet B, Jayaram HN, and Elford HL
- Subjects
- Animals, Drug Screening Assays, Antitumor, Female, Leukemia, Experimental enzymology, Male, Mice, Mice, Inbred Strains, Neoplasm Transplantation, Ribonucleotide Reductases analysis, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Benzamidines pharmacology, Leukemia, Experimental drug therapy, Ribonucleotide Reductases antagonists & inhibitors
- Abstract
Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of ribonucleotide reductase (EC 1.17.4.1) in extracts of L1210 cells by 50% (50% growth-inhibitory concentration, IC50) at 5 microM, whereas hydroxyurea, the only ribonucleotide reductase inhibitor in clinical use, exhibited an IC50 of 500 microM. Ribonucleotide reductase activity was also measured in situ by incubating L1210 cells for 24 h with trimidox at 7.5 microM, a concentration that inhibits cell proliferation by 50% (IC50) or at 100 microM for 2 h; these concentrations resulted in a decrease in enzyme activity to 22% and 50% of the control value, respectively. Trimidox and hydroxyurea were cytotoxic to L1210 cells with IC50 values of 7.5 and 50 microM, respectively. Versus ribonucleotide reductase, trimidox and hydroxyurea yielded IC50 values of 12 and 87 microM, respectively. A dose-dependent increase in life span was observed in mice bearing intraperitoneally transplanted L1210 tumors. Trimidox treatment (200 mg/kg; q1dx9) significantly increased the life span of mice bearing L1210 leukemia (by 82% in male mice and 112% in female mice). The anti-tumor activity appeared more pronounced in female mice than in male mice. Viewed in concert, these findings suggest that trimidox is a new and potent inhibitor of ribonucleotide reductase and that it is a promising candidate for the chemotherapy of cancer in humans.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.